8:31 am Immunomedics reported results from preclinical studies on the Co’s two investigational SN-38-containing antibody drug conjugates (ADCs), IMMU-130 and IMMU-132, that demonstrated a high therapeutic index for both agents.
View todays social media effects on IMMU
View the latest stocks trending across Twitter. Click to view dashboard
See who Immunomedics is hiring next, click here to view
